| Autor: |
Ridruejo E; Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, CEMIC, Avda. Las Heras 2939, Buenos Aires, Argentina. eridruejo@cemic.edu.ar, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG |
| Jazyk: |
angličtina |
| Zdroj: |
World journal of gastroenterology [World J Gastroenterol] 2007 Dec 28; Vol. 13 (48), pp. 6608-111. |
| DOI: |
10.3748/wjg.v13.i48.6608 |
| Abstrakt: |
Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid leukemia (CML) in blast crisis, accelerated or chronic phase, and also for advanced gastrointestinal stromal tumors. Severe hepatic toxicity and three deaths from hepatic failure have been reported. We report the case of a 51-year-old woman who was admitted to our institution with severe acute hepatitis. She was diagnosed with CML and began treatment with imatinib mesylate at a dose of 400 mg/d. Five months after beginning treatment, she developed severe hepatitis associated with coagulopathy, and was admitted to our institution. She had been consuming acetaminophen 500-1000 mg/d after the onset of symptoms. She had a progressive increase in bilirubin level and a marked decrease of clotting factor V. Five days after admission, grade II encephalopathy developed and she was referred for liver transplantation. Her clinical condition progressively deteriorated, and 48 h after being referred for transplantation she suffered a cardiac arrest and died. This report adds concern about the possibility of imatinib-mesylate-induced hepatotoxicity and liver failure, particularly in the case of concomitant use with acetaminophen. Liver function tests should be carefully monitored during treatment and, with the appearance of any elevation of liver function tests, treatment should be discontinued. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
